HealthCap

Tribune Therapeutics is a preclinical biopharmaceutical company dedicated to developing innovative medicines for the treatment of various fibrotic diseases. The company focuses on creating therapies that target the CCN protein family, a group of signaling proteins that play a crucial role in the development of fibrosis. By concentrating on these specific proteins, Tribune Therapeutics aims to provide effective treatment options for patients suffering from fibrotic conditions.

HelloBetter is a pioneering company in the field of digital therapeutics focused on mental health. Founded in 2015 in Hamburg, Germany, the company offers a range of online psychological training programs designed to address issues such as stress, depression, anxiety, and sleep disorders. Its programs have been validated through 33 randomized controlled trials, and six of them have received approval as prescription digital therapeutics under Germany's DiGA framework, allowing access for over 73 million people at no cost. The company's mission is to empower individuals to manage their mental health in a self-determined manner, utilizing evidence-based approaches. In addition to its therapeutic programs, HelloBetter provides resources like blogs and articles related to psychological health. With recent funding aimed at expanding beyond the DACH region, HelloBetter continues to enhance access to effective digital mental health care on a global scale.

SynOx Therapeutics is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that specializes in the development of innovative therapies for cancer. The company's primary focus is on emactuzumab, a humanized monoclonal antibody targeting CSF-1R, aimed at depleting macrophages within tumor tissues. This therapy is being investigated for its potential in treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Established in 2019, SynOx Therapeutics is backed by experienced investors in the biopharmaceutical field, emphasizing its commitment to addressing the unmet clinical needs of patients and improving their quality of life through advanced treatment options.

Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics and focused on rapidly advancing next generation transformative assets.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

SynOx Therapeutics is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that specializes in the development of innovative therapies for cancer. The company's primary focus is on emactuzumab, a humanized monoclonal antibody targeting CSF-1R, aimed at depleting macrophages within tumor tissues. This therapy is being investigated for its potential in treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Established in 2019, SynOx Therapeutics is backed by experienced investors in the biopharmaceutical field, emphasizing its commitment to addressing the unmet clinical needs of patients and improving their quality of life through advanced treatment options.

Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. Established in 2017, the company aims to enhance treatment options for oncology and immunology by creating small, non-antibody protein scaffolds. These Centyrins can be engineered as multi-specific therapeutics, enabling innovative mechanisms of action. They are designed to improve efficacy and safety profiles for patients suffering from cancer and other serious diseases, while also facilitating the targeted delivery of complex drug payloads, including nucleic acids. Aro Biotherapeutics is committed to advancing its wholly-owned pipeline of Centyrins, contributing to the field of genetic medicines.

Rampart Bioscience specializes in the development of gene medicines aimed at providing long-lasting treatments for a broad array of diseases. The company has created proprietary development and delivery platforms that enable the production of optimized therapeutics in a non-viral format. By integrating expertise from various scientific disciplines, such as gene delivery, protein sciences, and clinical translation, Rampart Bioscience focuses on assisting patients with genetically driven conditions, ultimately enhancing the effectiveness and safety of therapeutic interventions.

Vicore Pharma Holding is a clinical-stage pharmaceutical company that specializes in developing innovative treatments for severe lung disorders, particularly idiopathic pulmonary fibrosis (IPF). The company is advancing its lead drug candidate, C21, a small molecule angiotensin II type 2 receptor agonist, which is currently in phase 2a clinical development for IPF and has received orphan drug designation in both the EU and the US. In addition to C21, Vicore is exploring pre-clinical applications of the drug in other rare diseases associated with the AT2 receptor. The company is also developing Almee, a digital therapeutic that utilizes cognitive behavioral therapy to address the psychological challenges faced by patients with pulmonary fibrosis. Headquartered in Astra Zeneca’s Bioventurehub in Mölndal, Vicore Pharma aims to establish a comprehensive portfolio targeting respiratory diseases.

HelloBetter is a pioneering company in the field of digital therapeutics focused on mental health. Founded in 2015 in Hamburg, Germany, the company offers a range of online psychological training programs designed to address issues such as stress, depression, anxiety, and sleep disorders. Its programs have been validated through 33 randomized controlled trials, and six of them have received approval as prescription digital therapeutics under Germany's DiGA framework, allowing access for over 73 million people at no cost. The company's mission is to empower individuals to manage their mental health in a self-determined manner, utilizing evidence-based approaches. In addition to its therapeutic programs, HelloBetter provides resources like blogs and articles related to psychological health. With recent funding aimed at expanding beyond the DACH region, HelloBetter continues to enhance access to effective digital mental health care on a global scale.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.

Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers. 177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, is an antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

HelloBetter is a pioneering company in the field of digital therapeutics focused on mental health. Founded in 2015 in Hamburg, Germany, the company offers a range of online psychological training programs designed to address issues such as stress, depression, anxiety, and sleep disorders. Its programs have been validated through 33 randomized controlled trials, and six of them have received approval as prescription digital therapeutics under Germany's DiGA framework, allowing access for over 73 million people at no cost. The company's mission is to empower individuals to manage their mental health in a self-determined manner, utilizing evidence-based approaches. In addition to its therapeutic programs, HelloBetter provides resources like blogs and articles related to psychological health. With recent funding aimed at expanding beyond the DACH region, HelloBetter continues to enhance access to effective digital mental health care on a global scale.

Oncorena AB is a pharmaceutical company based in Göteborg, Sweden, dedicated to developing innovative treatments for cancer, specifically advanced or metastatic renal cancer. The company is focused on the compound orellanine, a toxin derived from certain mushroom species, which has demonstrated potent anti-tumor activity. Oncorena's primary objective is to confirm the efficacy and clinical benefits of orellanine in targeting renal proximal tubular epithelial cells that have transformed into cancer cells and formed metastases. By harnessing the selective properties of this compound, Oncorena aims to provide effective pharmacological solutions for patients suffering from advanced kidney cancer.

Elsa Science AB, founded in 2017 and based in Stockholm, Sweden, operates a digital health platform focused on rheumatoid arthritis. The company empowers patients to take an active role in their healthcare by providing tools that facilitate personal research into their condition. Through its application, users can monitor symptoms, diet, and lifestyle factors, gaining insights into how these elements influence their disease activity. Elsa collaborates with the Riskminder foundation and scientific studies at Karolinska Institutet to deliver reliable data and research findings. By enabling patients to track their responses to medications and overall health status, Elsa supports healthcare professionals in managing chronic diseases more effectively, improving treatment personalization and proactive care.

HelloBetter is a pioneering company in the field of digital therapeutics focused on mental health. Founded in 2015 in Hamburg, Germany, the company offers a range of online psychological training programs designed to address issues such as stress, depression, anxiety, and sleep disorders. Its programs have been validated through 33 randomized controlled trials, and six of them have received approval as prescription digital therapeutics under Germany's DiGA framework, allowing access for over 73 million people at no cost. The company's mission is to empower individuals to manage their mental health in a self-determined manner, utilizing evidence-based approaches. In addition to its therapeutic programs, HelloBetter provides resources like blogs and articles related to psychological health. With recent funding aimed at expanding beyond the DACH region, HelloBetter continues to enhance access to effective digital mental health care on a global scale.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Doctrin AB is a healthcare technology company based in Stockholm, Sweden, that offers a cloud-based platform aimed at helping healthcare providers digitize the patient journey. Founded in 2016, the platform facilitates information gathering, decision support, and documentation services, effectively simulating the way doctors conduct patient interviews. By automating and simplifying various aspects of patient visits, Doctrin enables healthcare professionals to enhance their efficiency and improve patient outcomes. The platform serves as a comprehensive tool for meeting, guiding, treating, and following up with patients, thereby contributing to the modernization and effectiveness of healthcare delivery.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. Established in 2017, the company aims to enhance treatment options for oncology and immunology by creating small, non-antibody protein scaffolds. These Centyrins can be engineered as multi-specific therapeutics, enabling innovative mechanisms of action. They are designed to improve efficacy and safety profiles for patients suffering from cancer and other serious diseases, while also facilitating the targeted delivery of complex drug payloads, including nucleic acids. Aro Biotherapeutics is committed to advancing its wholly-owned pipeline of Centyrins, contributing to the field of genetic medicines.

SynOx Therapeutics is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that specializes in the development of innovative therapies for cancer. The company's primary focus is on emactuzumab, a humanized monoclonal antibody targeting CSF-1R, aimed at depleting macrophages within tumor tissues. This therapy is being investigated for its potential in treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Established in 2019, SynOx Therapeutics is backed by experienced investors in the biopharmaceutical field, emphasizing its commitment to addressing the unmet clinical needs of patients and improving their quality of life through advanced treatment options.

InCarda Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, focused on developing innovative therapies for cardiovascular diseases. The company specializes in an inhaled drug delivery system aimed at treating acute paroxysmal atrial fibrillation, allowing patients to administer treatment quickly during the onset of symptoms. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic medication designed to provide rapid relief from arrhythmic events. This method allows for effective medication delivery directly to cardiac tissue, which enhances treatment efficacy and simplifies the management of atrial arrhythmias. InCarda Therapeutics has completed Phase 1 clinical trials and is progressing through Phase 2 with its lead product.

Priothera Ltd is a clinical-stage company based in Dublin, Ireland, with an additional location in Saint Louis, France. It specializes in the development of orally applied sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's primary focus is on its lead product, mocravimod, which is designed to enhance the curative potential of allogeneic haematopoietic stem cell transplants. By reducing the egress of T cell subsets from lymphatic tissues, Priothera's modulators aim to provide dual inhibition of graft versus host disease while also promoting graft versus leukemia effects, ultimately improving patient outcomes in this challenging area of medicine.

Doctrin AB is a healthcare technology company based in Stockholm, Sweden, that offers a cloud-based platform aimed at helping healthcare providers digitize the patient journey. Founded in 2016, the platform facilitates information gathering, decision support, and documentation services, effectively simulating the way doctors conduct patient interviews. By automating and simplifying various aspects of patient visits, Doctrin enables healthcare professionals to enhance their efficiency and improve patient outcomes. The platform serves as a comprehensive tool for meeting, guiding, treating, and following up with patients, thereby contributing to the modernization and effectiveness of healthcare delivery.

Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Aprea is a biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea Therapeutics was established in 2003 in Stockholms Lan, Sweden by Klas Wiman and Galina Selivanova.

Oncorena AB is a pharmaceutical company based in Göteborg, Sweden, dedicated to developing innovative treatments for cancer, specifically advanced or metastatic renal cancer. The company is focused on the compound orellanine, a toxin derived from certain mushroom species, which has demonstrated potent anti-tumor activity. Oncorena's primary objective is to confirm the efficacy and clinical benefits of orellanine in targeting renal proximal tubular epithelial cells that have transformed into cancer cells and formed metastases. By harnessing the selective properties of this compound, Oncorena aims to provide effective pharmacological solutions for patients suffering from advanced kidney cancer.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

InCarda Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, focused on developing innovative therapies for cardiovascular diseases. The company specializes in an inhaled drug delivery system aimed at treating acute paroxysmal atrial fibrillation, allowing patients to administer treatment quickly during the onset of symptoms. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic medication designed to provide rapid relief from arrhythmic events. This method allows for effective medication delivery directly to cardiac tissue, which enhances treatment efficacy and simplifies the management of atrial arrhythmias. InCarda Therapeutics has completed Phase 1 clinical trials and is progressing through Phase 2 with its lead product.

Modus Therapeutics AB is a clinical-stage drug development company based in Stockholm, Sweden, focused on creating pharmaceutical therapies. Founded in 2011, the company is developing sevuparin, a novel drug aimed at treating sickle cell disease, a painful inherited blood disorder that affects millions worldwide. In addition to its primary focus on sickle cell disease, Modus Therapeutics is also exploring the potential of sevuparin for treating conditions associated with severe systemic inflammation, such as sepsis, endotoxemia, and severe malaria, as well as anemia related to chronic inflammation, including kidney diseases. Through its innovative approach, Modus Therapeutics aims to improve patient outcomes and reduce healthcare costs associated with these disorders.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.

Doctrin AB is a healthcare technology company based in Stockholm, Sweden, that offers a cloud-based platform aimed at helping healthcare providers digitize the patient journey. Founded in 2016, the platform facilitates information gathering, decision support, and documentation services, effectively simulating the way doctors conduct patient interviews. By automating and simplifying various aspects of patient visits, Doctrin enables healthcare professionals to enhance their efficiency and improve patient outcomes. The platform serves as a comprehensive tool for meeting, guiding, treating, and following up with patients, thereby contributing to the modernization and effectiveness of healthcare delivery.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Tisbury Pharmaceuticals, Inc. is engaged in the discovery, development, and commercialization of therapies for the treatment of primary open angle glaucoma. Founded in 2017 and based in Beverly, Massachusetts, the company focuses on its clinical candidate, R-801, which aims to enhance fluid flow through the trabecular meshwork by utilizing redox catalysis and K+-ATP channel activation. This innovative approach targets the drainage openings in the eye, significantly reducing intraocular pressure in patients suffering from glaucoma.

Vivet Therapeutics SAS is a biotechnology company focused on researching, developing, and commercializing gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016 and based in Paris, France, the company employs a liver-targeting adeno-associated virus (AAV) vector to deliver therapeutic genes directly into hepatocytes, addressing genetic disorders at their source. Vivet is particularly known for its work on diseases such as Wilson disease, Progressive Familial Intrahepatic Cholestasis, and Citrullinemia Type I. In collaboration with the Fundacion para la Investigacion Medica Aplicada and the Centro de Investigación Medica Aplicada at the University of Navarra, Vivet aims to enhance gene delivery technologies and ensure long-term expression of therapeutic genes, thereby advancing the field of gene therapy for liver-related conditions.

Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.

Aprea is a biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea Therapeutics was established in 2003 in Stockholms Lan, Sweden by Klas Wiman and Galina Selivanova.

Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

LTB4 is developing a naturally occurring molecule stimulating the innate immunity system to target diseases such as infections and cancer.

IDEA AG is a biopharmaceutical company based in Munich, Germany, founded in 1993. The company specializes in the development and commercialization of non-invasive targeted therapeutics, primarily for dermatology and pain management. It focuses on delivering drugs through the skin using innovative Transfersome carriers, which facilitate the selective transport of established molecular weight drugs. One of its key products is Diractin, a ketoprofen formulation in a Transfersome gel designed to treat peripheral pain. IDEA AG aims to improve treatment outcomes for patients suffering from dermatological conditions and pain-related issues.

Altimmune, Inc. is a clinical stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of innovative treatments for liver disease, obesity, and vaccines. The company’s pipeline includes HepTcell, an immunotherapeutic candidate for chronic hepatitis B, which has successfully completed Phase I clinical trials. Altimmune also develops NasoShield, an intranasal anthrax vaccine, and NasoVAX, a recombinant intranasal vaccine. Additionally, the company is advancing AdCOVID, a single-dose intranasal vaccine for COVID-19. In the preclinical stage, Altimmune is working on ALT-801, a peptide-based dual GLP-1/glucagon receptor agonist for non-alcoholic steatohepatitis, as well as ALT-702, a tumor immunostimulant aimed at cancer treatment. The company employs proprietary technology for non-invasive intranasal delivery of its products and collaborates with institutions such as the University of Alabama at Birmingham to further its research initiatives.

Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company’s primary focus is on rare endocrine disorders, exemplified by its product candidates, Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Strongbridge also offers Keveyis, an oral carbonic anhydrase inhibitor approved for treating specific forms of periodic paralysis in the United States. Founded in 1996 and headquartered in Trevose, Pennsylvania, the company aims to leverage a concentrated prescriber base for its products and plans to utilize a targeted sales force for marketing in the U.S., European Union, and other key markets. Additionally, Strongbridge seeks to enhance its portfolio through the in-licensing or acquisition of complementary products that align with its focus on rare endocrine conditions.

Glionova AB is a development stage biopharmaceutical company based in Stockholm, Sweden, founded in 2014. The company focuses on developing therapies for challenging cancers, particularly glioblastoma, which is a common and aggressive primary brain tumor. Glionova is advancing its lead product, GLN-1001, an orally bioavailable small molecule designed to induce selective cell death in glioblastoma cells while sparing normal brain tissue. In addition to its research and development efforts, Glionova aims to market its product through strategic partnerships with global pharmaceutical companies that specialize in oncology.

Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company’s primary focus is on rare endocrine disorders, exemplified by its product candidates, Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Strongbridge also offers Keveyis, an oral carbonic anhydrase inhibitor approved for treating specific forms of periodic paralysis in the United States. Founded in 1996 and headquartered in Trevose, Pennsylvania, the company aims to leverage a concentrated prescriber base for its products and plans to utilize a targeted sales force for marketing in the U.S., European Union, and other key markets. Additionally, Strongbridge seeks to enhance its portfolio through the in-licensing or acquisition of complementary products that align with its focus on rare endocrine conditions.

Wilson Therapeutics is a biopharmaceutical company located in Stockholm, Sweden, focusing on the development of innovative therapies for rare diseases, particularly Wilson Disease. The company’s primary product, Decuprate®, is being investigated as a new treatment option for this condition and is currently undergoing evaluation in a Phase II clinical study involving patients with Wilson Disease. By targeting copper-mediated disorders, Wilson Therapeutics aims to address unmet medical needs in this specialized area of healthcare.

Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.

Ultragenyx Pharmaceutical is a biopharmaceutical company based in the United States that specializes in developing therapeutics for rare and ultra-rare diseases, particularly serious genetic disorders. The company focuses on identifying and commercializing innovative treatments that address significant unmet medical needs. Its product portfolio includes Crysvita, which is used to treat X-linked hypophosphatemia, and Mepsevii, indicated for Mucopolysaccharidosis VII. By leveraging existing scientific knowledge and emphasizing clear mechanisms of action, Ultragenyx aims to create impactful therapies for conditions that currently lack effective treatments. The company prioritizes efficient development strategies in a field characterized by limited information and established precedents, drawing on the management team's expertise to advance its mission of improving patient outcomes in rare disease populations.

BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.

SpineVision S.A. is a spinal technology company that specializes in the design, development, and marketing of implants and instrumentation for spinal treatment. Established in 1999 and headquartered in Antony, France, with subsidiaries in Belgium, Italy, the United Kingdom, and the United States, the company focuses on addressing a diverse range of spinal pathologies, including degenerative disc disease, deformities, cervical disorders, trauma, and tumors. Its product portfolio includes advanced systems such as Flex+, X-PLUS, LUMIS, and P.L.U.S., which offer various stabilization options and surgical solutions. Additionally, SpineVision provides specialized systems like the C3 anterior cervical plate and UNI-Thread, enhancing surgical procedures and outcomes. The company's innovations are developed in collaboration with prominent neurological and orthopedic surgeons, resulting in over 20 patents that reflect its commitment to advancing spinal care.

BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.

Ultragenyx Pharmaceutical is a biopharmaceutical company based in the United States that specializes in developing therapeutics for rare and ultra-rare diseases, particularly serious genetic disorders. The company focuses on identifying and commercializing innovative treatments that address significant unmet medical needs. Its product portfolio includes Crysvita, which is used to treat X-linked hypophosphatemia, and Mepsevii, indicated for Mucopolysaccharidosis VII. By leveraging existing scientific knowledge and emphasizing clear mechanisms of action, Ultragenyx aims to create impactful therapies for conditions that currently lack effective treatments. The company prioritizes efficient development strategies in a field characterized by limited information and established precedents, drawing on the management team's expertise to advance its mission of improving patient outcomes in rare disease populations.

Nexstim Plc is a medical technology company based in Helsinki, Finland, specializing in non-invasive brain stimulation technologies. Founded in 2000, it focuses on developing and marketing navigated transcranial magnetic stimulation (nTMS) systems, utilizing its proprietary SmartFocus technology with 3D navigation for precise targeting of brain regions. The company offers the NBT system for treating major depressive disorder and chronic neuropathic pain, as well as the NBS system for pre-surgical mapping of speech and motor cortices. Nexstim primarily serves universities and teaching hospitals, with a significant portion of its revenue generated in North America and its products marketed across Europe and internationally.

Cardoz AB manufactures anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The company was founded in 2006 and is based in Stockholm, Sweden.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Oncos Therapeutics Ltd. is a clinical-stage biotechnology company based in Helsinki, Finland, focused on developing targeted cancer immunotherapy products. The company is known for its lead product, ONCOS-102, which is an engineered human adenovirus designed to stimulate a systemic anti-tumor T cell response in cancer patients. Oncos Therapeutics utilizes its adenovirus-based platform to create therapies for various cancer types, including soft tissue sarcoma, ovarian cancer, and mesothelioma. Established in 2009, the company also runs an Advanced Therapy Access Program that began in 2007, providing individually tailored oncolytic virus therapies to patients who have not responded to standard treatments. This program has treated around 200 patients, demonstrating positive safety and efficacy outcomes. The scientific foundation for Oncos Therapeutics' developments lies in extensive research conducted at the University of Helsinki. As of July 2015, Oncos Therapeutics operates as a subsidiary of Targovax AS.

Immune Targeting Systems (ITS) Limited specializes in the development of synthetic vaccines aimed at combating mutating viruses. The company utilizes a T-cell vaccine platform that targets highly conserved viral antigens, directing the immune response specifically to infected cells. This innovative approach employs fluoropeptide vaccine technology, allowing for robust T-cell immunity without the need for potentially harmful adjuvants typically used to enhance vaccine efficacy. Founded in late 2003 and based in the London BioScience Innovation Centre, ITS has focused its efforts on creating vaccines for various viral infections, including seasonal and pandemic influenza, as well as life-threatening conditions such as HIV/AIDS and hepatitis. The company gained significant financial backing in 2007 from a group of investors, which included the Novartis Venture Fund and HealthCap, alongside support from the London Development Agency.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

BeneChill, Inc. is a medical device company based in San Diego, California, specializing in non-invasive cooling technologies aimed at enhancing patient outcomes following acute ischemic events, including cardiac arrest, stroke, and traumatic brain injury. Established in 2004, BeneChill has developed the RhinoChill System, which effectively reduces patient temperature to improve survival rates and recovery. The company operates primarily in the United States and Europe, focusing on innovative solutions for the healthcare sector.

Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of innovative anti-infectives aimed at women's health. Founded in 2008, the company offers products such as FemiFect, an antibiotic designed to treat infections associated with vaginitis caused by bacteria, fungi, and protozoa, and SPK-601, which targets human papillomavirus (HPV) and herpes simplex virus (HSV). Lumavita markets its products through various distributors, positioning itself within the expanding biopharmaceutical sector in Switzerland. The company was previously known as Shogoo Pharmaceuticals, AG before rebranding in December 2007 and operates as a subsidiary of Shogoo Pharmaceuticals KK.

Tengion is a clinical-stage biotechnology company focused on regenerative medicine, specializing in the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Tengion Neo-Bladder Augment, aimed at treating children with neurogenic bladder due to spina bifida and adults with neurogenic bladder resulting from spinal cord injury. Tengion's innovative approach seeks to eliminate the need for donor organs or anti-rejection medications by creating living cellular products that can regenerate or replace damaged tissues and organs. Additionally, the company has an investigational new drug application for its Neo-Urinary Conduit and plans to initiate a Phase 1 clinical trial for bladder cancer patients requiring bladder removal. Through its proprietary technology, Tengion aims to enhance patient outcomes by offering alternative solutions for organ and tissue repair.

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focused on developing and commercializing innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company's lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently undergoing Phase III trials for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and a Phase IIb trial for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing other drug candidates, including CCX140, an inhibitor targeting the CCR2 chemokine receptor, which has completed Phase II trials for diabetic nephropathy and is being developed for focal segmental glomerulosclerosis; CCX507, a second-generation CCR9 inhibitor that has completed Phase I trials; and CCX872, a selective CCR2 inhibitor currently in Phase Ib trials for stage 3 and 4 pancreatic cancer. ChemoCentryx aims to address the underlying immune system dysfunction associated with various conditions through its targeted therapeutics.

Tengion is a clinical-stage biotechnology company focused on regenerative medicine, specializing in the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Tengion Neo-Bladder Augment, aimed at treating children with neurogenic bladder due to spina bifida and adults with neurogenic bladder resulting from spinal cord injury. Tengion's innovative approach seeks to eliminate the need for donor organs or anti-rejection medications by creating living cellular products that can regenerate or replace damaged tissues and organs. Additionally, the company has an investigational new drug application for its Neo-Urinary Conduit and plans to initiate a Phase 1 clinical trial for bladder cancer patients requiring bladder removal. Through its proprietary technology, Tengion aims to enhance patient outcomes by offering alternative solutions for organ and tissue repair.

Nexstim Plc is a medical technology company based in Helsinki, Finland, specializing in non-invasive brain stimulation technologies. Founded in 2000, it focuses on developing and marketing navigated transcranial magnetic stimulation (nTMS) systems, utilizing its proprietary SmartFocus technology with 3D navigation for precise targeting of brain regions. The company offers the NBT system for treating major depressive disorder and chronic neuropathic pain, as well as the NBS system for pre-surgical mapping of speech and motor cortices. Nexstim primarily serves universities and teaching hospitals, with a significant portion of its revenue generated in North America and its products marketed across Europe and internationally.

Immune Targeting Systems (ITS) Limited specializes in the development of synthetic vaccines aimed at combating mutating viruses. The company utilizes a T-cell vaccine platform that targets highly conserved viral antigens, directing the immune response specifically to infected cells. This innovative approach employs fluoropeptide vaccine technology, allowing for robust T-cell immunity without the need for potentially harmful adjuvants typically used to enhance vaccine efficacy. Founded in late 2003 and based in the London BioScience Innovation Centre, ITS has focused its efforts on creating vaccines for various viral infections, including seasonal and pandemic influenza, as well as life-threatening conditions such as HIV/AIDS and hepatitis. The company gained significant financial backing in 2007 from a group of investors, which included the Novartis Venture Fund and HealthCap, alongside support from the London Development Agency.

OxThera AB is a biopharmaceutical company focused on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. Founded in 2005 and based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee, OxThera manufactures two main products: Oxabact and Oxazyme. Oxabact is an orally administered composition of live bacteria designed to enhance the removal of oxalate produced by the body, while Oxazyme is a non-systemic oral drug that contains recombinant oxalate decarboxylase, aimed at treating dietary hyperoxaluria and preventing kidney stones. The company holds worldwide patents for its innovative therapies and has received Orphan Drug designations for Oxabact in both Europe and the United States. Through its advanced biotherapy technologies, OxThera aims to improve kidney health and preserve organ function in patients affected by hyperoxaluria.

CoreValve is a private company founded in 2001 by Dr. Jacques Seguin, a cardiac surgeon, with the aim of innovating heart valve replacement technology. The company specializes in developing catheter-based aortic valve replacement procedures, allowing for the replacement of failing aortic heart valves without the need for surgical access. This innovative approach has successfully treated over 200 patients through the CoreValve ReValving™ procedure. While CoreValve primarily focuses on percutaneous aortic valve replacement, it plans to expand its efforts to include other minimally invasive treatments for structural heart diseases. Headquartered in Irvine, California, CoreValve is positioned in a region known for advancements in heart valve technologies.

BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.

CoreValve is a private company founded in 2001 by Dr. Jacques Seguin, a cardiac surgeon, with the aim of innovating heart valve replacement technology. The company specializes in developing catheter-based aortic valve replacement procedures, allowing for the replacement of failing aortic heart valves without the need for surgical access. This innovative approach has successfully treated over 200 patients through the CoreValve ReValving™ procedure. While CoreValve primarily focuses on percutaneous aortic valve replacement, it plans to expand its efforts to include other minimally invasive treatments for structural heart diseases. Headquartered in Irvine, California, CoreValve is positioned in a region known for advancements in heart valve technologies.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.

Tengion is a clinical-stage biotechnology company focused on regenerative medicine, specializing in the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Tengion Neo-Bladder Augment, aimed at treating children with neurogenic bladder due to spina bifida and adults with neurogenic bladder resulting from spinal cord injury. Tengion's innovative approach seeks to eliminate the need for donor organs or anti-rejection medications by creating living cellular products that can regenerate or replace damaged tissues and organs. Additionally, the company has an investigational new drug application for its Neo-Urinary Conduit and plans to initiate a Phase 1 clinical trial for bladder cancer patients requiring bladder removal. Through its proprietary technology, Tengion aims to enhance patient outcomes by offering alternative solutions for organ and tissue repair.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

Algeta ASA is an oncology company based in Oslo, Norway, dedicated to developing targeted therapies for cancer patients using its innovative alpha-pharmaceutical platform. The company's lead product, radium-223 dichloride, has successfully completed Phase III clinical trials for treating castration-resistant prostate cancer with bone metastases. Additionally, Algeta is advancing the development of thorium-227 conjugates, which involve linking the alpha-emitter to tumor-targeting molecules, currently in the preclinical phase. Algeta has established a collaboration with Bayer Pharma AG for the global development and commercialization of radium-223. Founded in 1997, the company originally operated under the name Anticancer Therapeutic Inventions AS before rebranding as Algeta ASA in 2003.

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland, dedicated to the discovery, development, and commercialization of treatments for autoimmune and inflammatory diseases. The company’s innovative approach centers on modifying epithelial permeability through compounds that regulate tight junctions in cell barriers. This technology has potential applications in various conditions, including celiac disease, asthma, chronic obstructive pulmonary disease (COPD), and acute lung injury. In addition, Alba Therapeutics focuses on therapeutic areas such as type 1 diabetes, inflammatory bowel disease (IBD), and mucosal vaccines, aiming to address a range of immune-mediated and inflammatory disorders.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Tengion is a clinical-stage biotechnology company focused on regenerative medicine, specializing in the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Tengion Neo-Bladder Augment, aimed at treating children with neurogenic bladder due to spina bifida and adults with neurogenic bladder resulting from spinal cord injury. Tengion's innovative approach seeks to eliminate the need for donor organs or anti-rejection medications by creating living cellular products that can regenerate or replace damaged tissues and organs. Additionally, the company has an investigational new drug application for its Neo-Urinary Conduit and plans to initiate a Phase 1 clinical trial for bladder cancer patients requiring bladder removal. Through its proprietary technology, Tengion aims to enhance patient outcomes by offering alternative solutions for organ and tissue repair.

OxThera AB is a biopharmaceutical company focused on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. Founded in 2005 and based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee, OxThera manufactures two main products: Oxabact and Oxazyme. Oxabact is an orally administered composition of live bacteria designed to enhance the removal of oxalate produced by the body, while Oxazyme is a non-systemic oral drug that contains recombinant oxalate decarboxylase, aimed at treating dietary hyperoxaluria and preventing kidney stones. The company holds worldwide patents for its innovative therapies and has received Orphan Drug designations for Oxabact in both Europe and the United States. Through its advanced biotherapy technologies, OxThera aims to improve kidney health and preserve organ function in patients affected by hyperoxaluria.

CoreValve is a private company founded in 2001 by Dr. Jacques Seguin, a cardiac surgeon, with the aim of innovating heart valve replacement technology. The company specializes in developing catheter-based aortic valve replacement procedures, allowing for the replacement of failing aortic heart valves without the need for surgical access. This innovative approach has successfully treated over 200 patients through the CoreValve ReValving™ procedure. While CoreValve primarily focuses on percutaneous aortic valve replacement, it plans to expand its efforts to include other minimally invasive treatments for structural heart diseases. Headquartered in Irvine, California, CoreValve is positioned in a region known for advancements in heart valve technologies.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

Five Prime Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, specializing in the discovery and development of innovative protein therapeutics. The company is advancing several product candidates, including Bemarituzumab, an antibody targeting fibroblast growth factor receptor 2b (FGFR2b), currently in Phase 3 clinical trials for gastric and gastroesophageal junction cancer. Other candidates include FPA150, a CD8 T cell checkpoint inhibitor in Phase 1a/1b trials for various cancers, and FPT155, a soluble CD80 fusion protein enhancing T cell co-stimulation, also in Phase 1a/1b trials. Additionally, Cabiralizumab, which inhibits colony stimulating factor-1 receptor, is undergoing Phase Ia/Ib trials in combination with other therapies. The company employs its ProScreen Engine to systematically screen all relevant human proteins, enabling rapid and high-quality therapeutic development. Five Prime Therapeutics has established collaborations and license agreements with several pharmaceutical companies, enhancing its research and development capabilities. Founded in 2001, the company continues to focus on advancing novel therapies for challenging cancer indications.

Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focused on developing and commercializing innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company's lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently undergoing Phase III trials for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and a Phase IIb trial for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing other drug candidates, including CCX140, an inhibitor targeting the CCR2 chemokine receptor, which has completed Phase II trials for diabetic nephropathy and is being developed for focal segmental glomerulosclerosis; CCX507, a second-generation CCR9 inhibitor that has completed Phase I trials; and CCX872, a selective CCR2 inhibitor currently in Phase Ib trials for stage 3 and 4 pancreatic cancer. ChemoCentryx aims to address the underlying immune system dysfunction associated with various conditions through its targeted therapeutics.